NASDAQ · Biotechnology

Rani Therapeutics Holdings, Inc. (RANI) Stock

$0.80 +0.88% NASDAQ: RANI Healthcare

Valuation

MetricValue
Price$0.80
Market Cap$52.19M
P/E Ratio-3.01
P/B Ratio3.87
P/S Ratio10.86
EPS (TTM)$-0.45
52-Week High$3.87
52-Week Low$0.45
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-129.93%
ROA-49.54%
ROCE-65.65%
Gross Margin-1900.00%
Operating Margin-1900.00%
Net Margin-618.02%
Debt/Equity0.09
Current Ratio4.08

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.0M$0$0$1.0M$2.0M
Operating Profit$-52.0M$-63.0M$-66.0M$-53.0M$-38.0M
Net Profit$-8.0M$-31.0M$-34.0M$-30.0M$-30.0M
EPS$-0.42$-1.28$-1.33$-1.05$-0.45
Op Margin-1899.1%——-5186.2%-2346.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$124.0M$108.0M$58.0M$37.0M$59.0M
Total Liabilities$3.0M$34.0M$32.0M$33.0M$17.0M
Cash$117.0M$27.0M$6.0M$4.0M$19.0M
Borrowings$0$30.0M$30.0M$30.0M$4.0M

Latest News

Daily – Vickers Top Buyers & Sellers for 07/22/2026 Argus Research · Jul 22, 2026 Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire · Jul 20, 2026 Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing GlobeNewswire · Jul 15, 2026 Rani Therapeutics Announces Research and Development Collaboration with PegBio to Expand Obesity Pipeline Across Multiple Novel Candidates GlobeNewswire · Jul 9, 2026 Rani Therapeutics Names Nicholas Maestas CFO MT Newswires · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-32.0M$-47.0M$-51.0M$-35.0M$-19.0M
Investing Cash Flow$-1.0M$-74.0M$29.0M$20.0M$-7.0M
Financing Cash Flow$0$-1.0M$0$0$0
Net Cash Flow$44.0M$-90.0M$-21.0M$-2.0M$15.0M
Free Cash Flow$-33.0M$-48.0M$-52.0M$-36.0M$-19.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.02
EV / EBITDA-1.61
FCF Yield-38.40%
Quick Ratio5.31
Interest Coverage-28.22
Return 1Y59.11%
Return 3Y-83.86%
Return 5Y—

Ownership

Insiders Held5.01%
Institutions Held43.88%
Institutions Float Held46.20%
Institutional HolderSharesReport Date
RA Capital Management, L.P.8,500,0002026-03-31
Samsara BioCapital, LLC8,500,0002026-03-31
AWM Investment Company, Inc.6,500,0002026-03-31
Vanguard Capital Management LLC4,622,5672026-03-31
SymBiosis Capital Partners, LLC3,667,5852026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
APLTApplied Therapeutics, Inc. $0.10 +0.00% -0.24 $14.86M 0.00%
CRBPCorbus Pharmaceuticals Holdings, Inc. $5.38 +2.09% -0.95 $99.68M 0.00%
CRDFCardiff Oncology, Inc. $1.11 +4.25% -1.87 $85.17M 0.00%
CYBNCybin Inc. $8.28 +1.22% -1.67 $413.02M 0.00%
ELTXElicio Therapeutics, Inc. $1.89 +4.42% -0.89 $36.04M 0.00%

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. is led by CEO Talat Imran, employs 105 people, headquartered in US, publicly traded since 2021.

Rani Therapeutics Holdings, Inc. (RANI) stock trades at $0.80 with a market capitalization of $52.19M. The stock is valued at a price-to-earnings (P/E) ratio of -3.01, price-to-book of 3.87, price-to-sales of 10.86. Over the past 52 weeks the stock has ranged between $0.45 and $3.87, and currently trades 79.3% below its 52-week high.

On profitability, Rani Therapeutics Holdings, Inc. generates a return on equity (ROE) of -129.93%, return on capital employed of -65.65%, an operating margin of -1900.00%, a net profit margin of -618.02%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.31 +0.33% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.67 +1.27%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides